PRIM, S.A. (BME: PRM) - Deep Dive Research Report

Report date: May 18, 2026

1. WHAT THE COMPANY DOES

In 1870, a pharmacist named Pedro Prim opened an orthopedic supplies shop on Calle del Barquillo in Madrid. The city was growing. Hospitals were rudimentary. Soldiers from the Carlist Wars had come home missing limbs. There was no system to supply artificial limbs, braces, or surgical instruments to Spanish patients, and no company making them locally. Pedro Prim decided that filling this gap was his business.

One hundred and fifty-six years later, the company he founded still operates under his name and still does fundamentally the same thing: it puts advanced healthcare products into the hands of Spanish patients and hospitals. It is listed on the Bolsa de Madrid (1985), employs approximately 984 people, and operates from a headquarters in Móstoles (Madrid), two manufacturing facilities, seven commercial delegations, four distribution warehouses, and six orthopedic retail centers. Export relationships span 93 countries.

The core value proposition divides cleanly into two activities that sit at different points in the healthcare supply chain.

The first activity is the hospital division, called Tecnología Sanitaria (Healthcare Technology). Here, Prim acts as the commercial arm of major international medical device manufacturers who need a trusted local partner to reach Spanish hospitals. International manufacturers - whether a Chinese patient monitoring company like Mindray, or a US surgical robotics company like Globus Medical - face the same problem: Spanish hospital procurement is relationship-driven, regionally fragmented, and bureaucratically complex. A foreign manufacturer cannot easily build its own Spanish salesforce and service network for a product category that may represent €5-10M of Spanish revenue. Prim can. It employs specialist teams in neurosurgery, cardiovascular, neuromodulation, endosurgery, ENT, operating room, plastic surgery, traumatology, and biomaterials - seven distinct clinical specialties, each requiring deep knowledge of the hospital department it serves. Prim handles clinical demonstrations, negotiates with procurement offices, trains surgical teams, and services the equipment post-installation. In early 2024, for instance, Prim placed the first Excelsius GPS robotic spinal surgery system (Globus Medical) at Hospital La Paz in Madrid - the first Spanish public or private hospital to use the technology. Prim announced in 2024 that it had assumed distribution of Mindray's Patient Monitoring and Life Support line across four autonomous communities of Spain. These are not commodity distribution deals; they are multi-year clinical partnerships where Prim's relationships with hospital department heads are the asset.

The second activity is Movilidad y Cuidados de la Salud (Mobility and Healthcare) - the orthopedics and mobility aids division. This is both a manufacturer and a distributor. On the manufacturing side, Prim designs and produces orthopedic supports - braces, collars, splints, compression garments, plantar insoles, walking aids - under thirteen proprietary brand names: AIRMED, AIRTEX, AQTIVO, BEBAX, CAMP, COMFORSIL, ELCROSS, MY PRIM KIDS, NEOPRAIR, PRIM, PRIMSPINE, PRIMMAX, and SPINAIR. These products are manufactured at Prim's own facilities and at Italian subsidiaries acquired in 2022. On the distribution side, Prim is what it calls "the only nationwide distributor in Spain that covers every orthopedic need" - including products from international brands it doesn't manufacture but has chosen to represent.

The products reach patients through multiple channels: hospital orthopedic departments, outpatient physiotherapy clinics, independent orthopedic centers, pharmacies, podiatry practices, and Prim's own retail orthopedic establishments. The company has described itself as "at health's service" across all stages of the patient mobility journey - from acute hospital intervention through rehabilitation to long-term mobility support.

What makes this business hard to replicate is less about intellectual property than about institutional relationships. A hospital neurosurgery department that has trusted Prim's specialist salespeople for twenty years does not easily switch to an unknown distributor. An orthopedic center that stocks Prim-branded braces and has been trained to fit them does not casually add a competitor's range. The switching friction is embedded in relationships, logistics infrastructure, and clinical familiarity rather than legal contracts - which makes it durable but also makes it hard to measure.

2. BUSINESS SEGMENTS

2.1 Healthcare Technology (Tecnología Sanitaria)

This segment is the hospital distribution business. Prim serves as the Spanish commercial partner for international medical device manufacturers who cannot economically justify building their own Spanish direct-sales infrastructure for their products.

The segment operates across seven clinical specialty areas: neurosurgery, cardiovascular systems, neuromodulation, endosurgery, ENT (ear, nose, and throat), operating room equipment, and plastic surgery/traumatology/biomaterials. Each of these is a distinct clinical world - a neurosurgeon and a cardiovascular surgeon are not interchangeable customer relationships. Prim employs teams specialized per clinical area, capable of attending procedures, explaining device mechanics, and navigating clinical evidence discussions with specialist physicians.

The types of products are high-value, low-volume capital equipment and disposables. Robotic spinal surgery systems (like the Excelsius GPS by Globus Medical) cost hundreds of thousands of euros per installation. Patient monitoring platforms from Mindray require ongoing support contracts. These are not products sold from a catalogue; they are installed, trained on, and maintained over multi-year cycles.

This segment has been growing faster than the Mobility division. In Q1 2026, despite the broader disruption from Spain's national doctors' strike, Healthcare Technology grew 5% year-over-year - demonstrating that its hospital capital equipment contracts are partially insulated from short-term prescription disruptions that hit orthopedics harder.

The core capability Prim has built here is specialist clinical knowledge by therapeutic area, married to a nationwide commercial and service network that no single foreign manufacturer would build just for Spain. This is a business where relationships with heads of neurosurgery or cardiology departments - built over years of collaborative case support - are the primary competitive asset.

2.2 Mobility and Healthcare (Movilidad y Cuidados de la Salud)

This is the larger of the two segments by revenue and represents the original heritage business. It sits in a different part of the healthcare supply chain: rather than selling one expensive robot to one hospital department, this segment sells millions of braces, collars, and compression products to thousands of pharmacies, orthopaedic centers, and individual patients.

Prim is a manufacturer here. Its factories in Móstoles and through Italian subsidiaries Easytech (Florence) and Teyder (Barcelona) produce own-brand orthopedic supports. The manufacturing process for orthopedic braces involves technical textile engineering - designing products that provide controlled compression or immobilization while being comfortable enough for long-term wear, meeting EU MDR certification requirements, and being manufacturable at scale. The PRIMSPINE brand focuses on spinal supports; AQTIVO on active lifestyle bracing; BEBAX and SWASH on pediatric orthopedic needs (SWASH is a specific hip abduction brace used in pediatric neurological conditions); AIRMED on medical compression; COMFORSIL on silicone-based foot orthotics. Each product range requires design expertise, material sourcing relationships, clinical validation, and regulatory certification.

The subsidiary Establecimientos Ortopédicos Prim SA operates six to seven retail orthopedic clinics in Madrid and Galicia, providing a direct-to-consumer channel where patients can be professionally fitted for custom orthoses and prostheses. This is a small but differentiated capability - most of Prim's competitors distribute through third-party orthopaedic centers rather than owning retail points.

This segment was more exposed in Q1 2026 to Spain's national doctors' strike, which directly reduced orthopedic prescriptions and hospital rehabilitation activity. Revenues declined 2% in Q1 2026 against a prior-year quarter where they had been strong. Management characterized this as temporary and non-structural, pointing to March 2026 recovering to +4% year-over-year as prescriptions normalized.

The scale of this segment - spanning hospitals, pharmacies, orthopaedic centers, podiatry practices, and individual consumers - gives Prim exceptional distribution breadth that a manufacturer without its commercial network could not replicate. Prim describes itself as the only nationwide Spanish distributor that can cover every orthopedic need, a claim that speaks to the fragmented nature of the Spanish orthopedic distribution market, where most distributors are regional or category-specific.

Segment context in 2021-2025 strategic plan: Management has disclosed that during the concluded 2021-2025 plan, the group shifted focus toward higher-margin business lines. Gross margin expanded from approximately 46% in 2022 to 50% in 2025 - a 400 basis point expansion driven by mix shift, pricing discipline, and procurement cost improvement (benefiting from a stronger euro against the US dollar for product imports). The Healthcare Technology segment, with its more complex products and higher clinical value, likely contributed disproportionately to this margin improvement.

Note on the spa/wellness division: Earlier years saw Prim operate a Spa/wellness segment (Prim Spa), including hotel and resort wellness projects in Mexico and Spain. The 2024 annual results explicitly adjusted for "la plusvalía en la venta del negocio de SPA" (gain on sale of the SPA business), confirming that this division was divested or wound down during 2024. This disposal helped clean up the reporting structure and refocus the business on its core healthcare activities.

3. PRODUCTS AND BUSINESS DETAIL

Full product catalogue

The orthopedic support range covers essentially every body part and clinical need. Upper limb products include collar/cervical braces (soft to rigid), clavicle braces, arm slings, shoulder orthoses, elbow braces, wrist supports, and finger/thumb immobilizers. Lower limb products include hip abduction braces (including the specialized pediatric SWASH system), thigh supports, knee orthoses (functional, unloading, and post-surgical types), ankle braces, calf supports, and foot orthoses. Spinal supports cover lumbar, thoracic, and cervical/thoracic-lumbar regions under the PRIMSPINE and SPINAIR brands. The COMFORSIL brand specifically addresses silicone-based plantar insoles and foot corrections. AIRMED handles medical-grade compression hosiery (stockings, sleeves). MY PRIM KIDS is the pediatric line.

Internationally, Prim represents and distributes products from companies such as CAMP (Canadian brand for pediatric orthopedics, scoliosis management, and activity bracing) - notably, the CAMP brand appears in Prim's portfolio alongside its own brands, suggesting a long-term distribution agreement or brand licensing arrangement.

The hospital technology product range is defined by the seven clinical specialties: robotic surgery systems, patient monitoring platforms (Mindray), cardiovascular devices, neuromodulation implants, endoscopic surgery instruments, operating room infrastructure (tables, lights, imaging), ENT systems, and reconstructive/plastic surgery materials.

In 2024, Prim also entered the neurological early diagnosis space through its 20% stake in Aura Innovative Robotics - a Spanish startup using robotics to identify biomarkers of Parkinson's disease and other neurodegenerative conditions through movement analysis. This partnership, announced October 2023 alongside an alliance with Fundación de Investigación HM Hospitales, represents a nascent position in digital diagnostics that connects both Prim segments - it uses hospital relationships (Healthcare Technology) to place a device that primarily benefits outpatient and long-term care (Mobility & Healthcare).

Manufacturing and operations

Two manufacturing facilities exist within the group: the primary facility in Móstoles (Madrid), and manufacturing capacity added through the 2022 acquisitions. Easytech SRL in Florence, Italy - acquired in October 2022 for part of the €13.3M total acquisition spend - produces orthopedic products with reported 2021 revenues of €2.7M. Teyder, based in Barcelona with 30+ years of market presence and 2021 revenues of €3.3M, brought advanced textile manufacturing capabilities for orthoses, electric mobility products, and technical aids. Laboratorios Herbitas (Valencia) brought pharmaceutical/medical consumables expertise.

The 2022 acquisitions cost €13.3M in total and were explicitly positioned as the inorganic leg of the 2021-2025 strategic plan. Since then, Prim has focused on organic integration and margin extraction rather than further acquisitions. The FY 2025 press release noted that the full-year revenue growth of 8% was "achieved entirely organically" - signaling that the acquisition phase of the prior plan is complete and the next strategic cycle (2026-2031, to be presented May 21, 2026) will define the next inorganic strategy.

Geographies

Spain dominates revenues. Prim's export network reaches 93+ countries, and the Italian operations give a small European manufacturing footprint, but the company is fundamentally a Spanish domestic business. International activity is primarily through distribution partnerships rather than owned subsidiaries (except Italy). The 2026-2031 strategic plan announcement says it will combine "organic growth with financial discipline" and position itself for "internal and external opportunities" - suggesting selective inorganic activity in specific geographies or product lines may be on the horizon.

Digital transformation - Project Kairós

The FY 2025 annual report described Project Kairós as the beginning of a new customer relationship management model through a digital ecosystem. This is Prim's CRM implementation - standardizing and digitizing how its commercial teams interact with hospital procurement officers, orthopaedic center owners, and pharmacy clients. Alongside this, the group implemented an enhanced ERP platform and AI-powered productivity tools. These investments are aimed at making the commercial process more measurable and the logistics operations more efficient - both prerequisites for scaling without proportional headcount growth.

4. CUSTOMERS

Prim's customer base divides into two largely distinct pools that mirror the two business segments.

Hospitals and clinical institutions are the primary customers for the Healthcare Technology division. The purchase decision sits with the heads of specialist departments - the Chief of Neurosurgery, the Head of Interventional Cardiology, the Operating Room Manager - advised by procurement committees. These decisions involve multi-stage evaluation: clinical demonstration, trial period, procurement committee approval, budget allocation, and often public tender (since most large Spanish hospitals are publicly owned). The sales cycle for a capital equipment system can be 12-24 months. Once a system is installed, switching is costly - not just financially but in terms of clinical workflow disruption and retraining. Prim's long-standing specialist salespeople maintain ongoing relationships with these department heads, attending procedures and providing clinical support - creating a relationship depth that a new entrant would take years to build.

Orthopaedic centers, pharmacies, and healthcare professionals are the primary customers for the Mobility and Healthcare division. An orthopedic center owner makes buying decisions based on product quality, price, delivery speed, marketing support, and the clinical training Prim provides on product fitting. Pharmacies buy compression hosiery and foot care products based on brand recognition and margin. Individual patients interacting with the Establecimientos Ortopédicos Prim retail centers need to be fitted by trained orthotists.

Switching costs in orthopedics distribution are moderate. An orthopaedic center can try a competitor's brace brand and switch relatively easily. However, Prim's product breadth - being described as the only nationwide full-range orthopedic distributor - means that an orthopaedic center working with Prim can consolidate purchasing across all body parts and clinical needs with a single supplier. The operational convenience of fewer supplier relationships, combined with Prim's clinical training support, creates retention incentives beyond simple product quality.

Insurance companies and mutual insurance funds (mutuas) are an important indirect customer, particularly in orthopedics. When a mutual fund or private insurer covers a patient for a work-related injury or elective procedure, they direct patients to specific networks of orthopaedic and rehabilitation providers. Prim's relationships with these insurers help maintain preferred-supplier status within their networks.

No disclosed customer concentration - Prim does not identify any single customer as representing more than a defined percentage of revenue, suggesting the business is distributed across many hospital departments, orthopaedic centers, and pharmacies rather than dependent on one or two anchor relationships.

5. COMPETITIVE LANDSCAPE

The competitive landscape differs significantly across the two segments.

Healthcare Technology - hospital distribution

Prim's primary competition here is the direct sales subsidiaries of the multinational manufacturers themselves. Companies like Medtronic, Stryker, Johnson & Johnson DePuy Synthes, Siemens Healthineers, GE Healthcare, and Olympus all operate directly in Spain with their own specialist salesforces for their highest-volume and highest-margin product lines. They do not need local distributors for products where their Spanish revenue justifies direct infrastructure.

Prim therefore wins the distribution relationships for manufacturers where the Spanish market is too small or too specialized to justify direct infrastructure, or where the manufacturer has chosen to use Spain as a tested market before building direct. The Mindray arrangement (patient monitoring in four autonomous communities) is illustrative - Mindray's global ambition in hospital monitoring puts it in direct competition with Philips, GE, and Drager, and rather than build a Spanish salesforce from scratch across all 17 autonomous communities simultaneously, it partners with established distributors like Prim in specific regions.

The barrier to entry for a new hospital distribution company in Spain is primarily relationship-based. A new distributor cannot simply offer to distribute Globus Medical's Excelsius GPS at competitive prices; Hospital La Paz's neurosurgery chief is choosing a clinical partner whose team they trust, not just a product supplier. These relationships take years to build and require genuine clinical credibility. Prim's 150-year institutional presence and specialist teams represent a genuine barrier.

Mobility and Healthcare - orthopedics

The global competitors in orthopedic supports and bracing are primarily Northern European and American firms: Ottobock (Germany, private, €1.1B+ revenue) is the dominant global orthopedic and prosthetics company; Ossur (Iceland, listed on Nasdaq Iceland) specializes in prosthetics and advanced bracing; Bauerfeind (Germany, private) is focused on orthopedic supports and compression hosiery; DJO Global / Enovis (US, NYSE: ENOV) produces the DonJoy and other brace brands; Össur (Iceland) is strong in functional knee bracing. In Spain, these manufacturers either sell directly through their own distributors or license distributors for specific product categories.

Prim's competitive position in orthopedics rests on three factors. First, own-brand manufacturing provides margin control - Prim earns the manufacturer's margin on PRIM-brand braces rather than just a distribution margin on a third-party product. Second, nationwide distribution coverage means that a single orthopaedic center across any Spanish region can be served, which a regionally focused competitor cannot match. Third, the Establecimientos Ortopédicos Prim retail network provides a direct-to-patient channel that most distributor-only competitors lack.

Where Prim is exposed: in the premium functional bracing segment (post-ACL surgery, ski bracing, athletic protection), brands like DonJoy, Ossur, and Bauerfeind have stronger clinical brand recognition and direct relationships with sports medicine physicians and physiotherapy clinics. Prim's own brands are stronger in the higher-volume medical support/rehabilitation market than in the premium sports and athletic segment.

Structural dynamics

The Spain medical devices market is dominated by imports - Germany alone accounts for roughly 50% of imports - and only about 6% of devices used in Spain are manufactured locally. This means domestic manufacturers like Prim occupy a specific niche: products where local manufacturing delivers cost or regulatory advantages, combined with distribution capabilities for imported products.

Small and medium enterprises comprise 90% of companies in Spanish medical devices but generate only 40% of sales. Large firms (including Prim at its scale) generate the remaining 60%. This means Prim sits above the typical SME but below the multinational giants - a position that allows it to be a genuine nationwide player in orthopedics and a meaningful hospital technology distributor, without the resources to compete directly with the global MedTech majors in their core product categories.

6. INDUSTRY

What drives demand

The fundamental demand driver for Prim's products is Spain's aging population. Spain has one of the oldest demographics in Europe, with a median age of approximately 46 years and 20%+ of the population over 65. This creates structural demand for orthopedic supports (arthritic joints, osteoporotic fractures, postural deterioration), rehabilitation products (post-surgical recovery from joint replacements), and hospital technology in the specialties where age-related conditions are most prevalent (cardiovascular disease, neurodegenerative conditions, spinal degeneration).

Beyond demographics, Spain's healthcare expenditure has grown consistently. Total healthcare spending reached approximately USD 136.5 billion (9.3% of GDP) in 2021, up from lower levels in prior years. Per capita healthcare spending of approximately $2,450 annually and Spain's universal healthcare system - which covers the vast majority of diagnostic and surgical procedures - ensures stable institutional demand for medical devices and orthopedic products.

Surgical volume growth in Spain is a specific tailwind for the hospital technology segment. As the Spanish population ages and the backlog from COVID-era deferred procedures works through the system, volumes in joint replacement, spinal surgery, cardiovascular procedures, and neurological interventions have been growing. Each additional surgery requires the products and devices that Prim distributes.

Market size

The Spain medical devices market was approximately €6-7 billion in 2021-2022, growing at a mid-single-digit CAGR. The Spain orthopedic devices market specifically was approximately €941 million in 2023, projected to grow at a 6.7% CAGR to approximately €2 billion by 2035 (per market research estimates, which should be treated as directional rather than precise).

Regulatory environment

The EU Medical Device Regulation (EU MDR, 2017/745) took full effect in 2024, replacing the older Medical Device Directive. This created a more rigorous certification pathway for medical devices sold in Europe, requiring more clinical evidence and more extensive post-market surveillance. The short-term effect was to slow some product launches and increase compliance costs. The long-term effect may favor larger players like Prim who have established regulatory affairs capabilities over smaller regional competitors who struggle with the compliance burden.

For hospital procurement specifically, Spain operates through public tendering (licitaciones) for large hospitals, which introduces procurement cycle variability - a hospital's budget cycle and tender calendar dictates when purchases happen, not the customer's immediate clinical need. This creates quarterly lumpiness in Prim's hospital technology revenue and explains why management tends to discuss performance over rolling nine-month periods rather than individual quarters.

Cyclicality

Demand for orthopedic and hospital products is structurally defensive - people need braces and surgical equipment regardless of economic cycles. However, Prim's revenue is not fully immune to disruption. The Q1 2026 results demonstrated that healthcare system disruptions (a nationwide doctors' strike) can materially affect prescription volumes and hospital activity, creating significant short-term earnings impact. Weather events also affect patient mobility and elective procedure rates. These are not economic cycle effects but operational disruptions specific to the healthcare delivery system.

Import substitution dynamics are relevant but limited. Prim manufactures some products domestically but is also a significant importer (particularly for hospital technology products made by global manufacturers). The strengthening of the euro against the US dollar in 2024-2025 specifically benefited Prim's procurement costs for dollar-denominated products - a benefit management explicitly called out in results commentary across multiple reporting periods.

7. GROWTH TRIGGERS

Prim SA does not hold traditional Western-format earnings conference calls with analyst Q&A. Instead, the company files quarterly results presentations (Presentaciones de Resultados) with Spain's CNMV regulator, which serve as the primary source of management forward guidance. The four presentations referenced below are the most recent four filings as of May 18, 2026.

• New 2026-2031 strategic plan to be presented May 21, 2026, combining organic growth with financial discipline and positioning the group for "internal and external opportunities" - signaling the possibility of targeted inorganic activity. This is the company's most significant near-term catalyst and will define expectations for the next six years. (Q1 2026 results presentation, May 4, 2026)

"The company will present a new strategic roadmap on May 21, emphasizing organic growth paired with financial discipline while positioning itself for internal and external opportunities."

• March 2026 recovery confirms business model normalization after Q1 2026 disruption. March sales grew 4% year-over-year, validating that January-February weakness from the doctors' strike and adverse weather was temporary. (Q1 2026 results presentation, May 4, 2026)

• Healthcare Technology division growing at 5% in Q1 2026 even during the disrupted quarter, demonstrating that the hospital capital equipment business is structurally decoupled from the prescription-driven orthopedics business. (Q1 2026 results presentation, May 4, 2026)

• New board executive Ignacio Prim Martínez (5th generation of the founding family) appointed as executive director in December 2025, and extraordinary shareholders' meeting held to approve this alongside Guillermo Comenge Valencia as dominical director. This signals a formal governance transition and potentially a more active ownership voice in strategic direction as the 2026-2031 plan is launched. (Q3/9M 2025 results presentation, October 28, 2025)

• Project Kairós CRM implementation - a new digital customer relationship management ecosystem begun in 2025 - expected to improve commercial productivity and customer retention measurement across orthopedics distribution channels. Management described it as "marking the beginning of a new customer relationship management model." (FY 2025 results presentation, February 6, 2026)

• Margin expansion trajectory: Gross margin reached 50% in FY 2025 (up from 46% in 2022). Management described the improvement as driven by: (i) product mix shift toward higher-margin lines, (ii) pricing discipline, and (iii) favorable EUR/USD exchange rate on procurement. Management guidance implies continued focus on mix improvement in the new strategic plan. (FY 2025 results presentation, February 6, 2026)

"2025 closes a transformative, distinctive strategic plan with solid financials, peak margins, and a prepared team." - Fernando Oliveros (Executive Advisor), FY 2025 results presentation

• Working capital improvement: Prim generated €11M in cash in FY 2025, driven by improved inventory rotation and faster customer payment collection. The collection period improved by 8 days over 9M 2025 vs. prior year. This generates investable cash for the new strategic plan period without requiring new debt. (9M/Q3 2025 results presentation, October 28, 2025; FY 2025 results presentation, February 6, 2026)

• Zero net financial debt maintained entering 2026, with cash position of €22.5M and €16M+ of undrawn credit facilities. This clean balance sheet gives full optionality for either organic investment or inorganic acquisitions in the new strategic plan without leverage risk. (Q1 2026 results presentation, May 4, 2026)

• Dividend growth commitment: Proposed dividend of €0.53/share for FY 2025 represents +18% growth, suggesting management confidence in sustainable earnings improvement. The Board's track record of paying growing dividends aligns dividend policy with strategic confidence. (FY 2025 results presentation, February 6, 2026)

8. KEY RISKS

1. Spanish healthcare system concentration

More than 90% of Prim's revenue is generated in Spain. Spain's public healthcare system (Sistema Nacional de Salud) is simultaneously Prim's biggest customer and its biggest regulatory counterparty. Any meaningful change to how Spain procures medical devices - centralized national procurement platforms, tighter budget controls, delayed hospital capital expenditure - disproportionately affects Prim. Unlike a company selling into multiple European markets, Prim cannot redirect sales efforts if Spain slows. This is a high-probability moderate-drag risk given ongoing fiscal pressures in Spanish public health budgets.

2. Doctors' strike and healthcare delivery disruption

Q1 2026 demonstrated this risk mechanism clearly: a national doctors' strike in January-February 2026, with weekly regional stoppages and high participation across several autonomous communities, caused a 32.6% drop in net profit despite revenues remaining essentially flat. The mechanism is specific to orthopedics and rehabilitation: prescriptions for orthopedic supports and rehabilitation equipment require physician authorization. When doctors stop working, prescriptions stop. Hospital activity drops. Sales of orthopedic consumables decline. The risk is concentrated in the Mobility & Healthcare segment and is correlated with any form of healthcare system disruption (strikes, pandemic-era capacity reduction, extreme weather affecting patient mobility). Management classified Q1 2026 as "cyclical and non-structural" - which was subsequently validated by March's recovery - but repeat episodes would undermine confidence in earnings predictability.

"We observed a national strike of doctors in January-February with high participation in various autonomous communities, leading to a temporary reduction in hospital activity and prescriptions, especially in orthopedics and rehabilitation." - Q1 2026 results presentation, May 4, 2026

3. Competition from manufacturer direct subsidiaries

The Hospital Technology segment's strategic vulnerability is that Prim's distribution relationships exist precisely because the manufacturer has chosen not to build direct Spanish infrastructure. If a manufacturer grows large enough in Spain, or decides to invest in building direct sales capability, it may terminate the distribution agreement. This is an ongoing risk for any distributor-dependent model. The loss of one meaningful distribution agreement (for example, if Mindray expanded from four to all seventeen autonomous communities through a direct subsidiary) would create a revenue gap that would be difficult to replace quickly with alternative manufacturer relationships.

4. Foreign exchange - EUR/USD procurement exposure

Prim imports significant volumes of products priced in US dollars. The 2024-2025 period benefited from a strong euro, which management explicitly cited as contributing to gross margin expansion. A reversal of EUR/USD to weaker euro levels would put upward pressure on procurement costs and compress gross margins, potentially reversing some of the margin progress achieved in the 2021-2025 strategic plan.

5. Management transition risk

Three simultaneous changes are occurring in Prim's leadership structure: CFO Alberto Iriondo departed in April 2026 after eight years (replacement not yet named as of May 18, 2026); Ignacio Prim Martínez joined as executive director in December 2025 (representing the 5th generation of the founding family); and the company is entering a new six-year strategic plan with a new leadership configuration. The departure of a long-serving CFO at the start of a new strategic cycle creates execution risk - the incoming CFO will need time to develop institutional knowledge, lender relationships, and a working dynamic with the executive team. This is a low-probability but meaningful risk: poorly executed management transitions in family-controlled companies can result in governance tension between the family's directional ambitions and professional management's operational reality.

6. Working capital intensity and hospital payment cycles

Spanish public hospitals are notorious for slow payment. Accounts receivable management has been a major focus of Prim's 2021-2025 plan - collection periods improved by 8 days in 9M 2025 vs. prior year and by 1.5 days in Q1 2025 vs. year-end 2024. This suggests improvement is ongoing. However, hospital budget cycles can cause payment delays that absorb significant working capital, particularly if a new strategic plan accelerates growth in the hospital technology division (where individual contracts are larger and payment timing more variable).

7. EU MDR compliance and product portfolio complexity

The EU Medical Device Regulation (2017/745) imposes more stringent clinical evidence requirements and ongoing post-market surveillance obligations on all medical devices sold in Europe. For a company with Prim's product breadth - thirteen orthopedic brands across hundreds of SKUs plus hospital technology devices from multiple manufacturers - the compliance workload is substantial. Any product that fails to achieve or maintain CE marking under the new regulation must be withdrawn from market. This risk is manageable for Prim's established core products but could affect newer or peripheral product lines.

9. WALK THE TALK

The four reporting periods used: H1 2025 (filed September 9, 2025), 9M/Q3 2025 (presented October 28, 2025), FY 2025 (presented February 6, 2026), Q1 2026 (presented May 4, 2026).

Note: Prim SA does not conduct traditional earnings calls with analyst Q&A. The company files results presentations with Spain's CNMV regulator quarterly, which serve as the primary source of management commentary and guidance.

The 2021-2025 strategic plan is the most important baseline for assessing management credibility, because it sets out the explicit multi-year promises against which outcomes can be measured.

The plan announced three pillars: growth, profitability, and sustainability. On growth: revenues expanded from approximately €168 million in 2021 to €251.8 million in 2025 - compounded annual growth of approximately 10% over four years, achieved entirely organically once the 2022 acquisition phase was complete. Management promised ambitious growth and delivered it. On profitability: gross margin expanded from approximately 46% in 2022 to 50% in 2025, EBITDA grew from approximately €18-20 million in 2022 to €33.9 million in 2025, and net profit went from approximately €8-10 million in 2022 to €16.7 million in 2025. The CEO Fernando Oliveros stated that "2025 closes a transformative, distinctive strategic plan with solid financials, peak margins, and a prepared team" - and the numbers support that characterization. Management's track record across the full plan period is one of credible delivery.

Looking at the four most recent reporting periods specifically:

The H1 2025 filing (September 2025) showed revenues growing approximately 10% year-over-year with EBITDA up 28.6% and operating result up 44%, building on strong Q1 2025 momentum (+9.4% revenues, +24.9% EBITDA). Management's narrative through mid-2025 emphasized margin expansion, working capital improvement, and the completion of the 2021-2025 plan on strong terms.

The Q3/9M 2025 presentation (October 28, 2025) revealed continued strong performance with nine-month revenues of €182.1M (+7.4%) and EBITDA of €24.5M (+31.5%). Crucially, management used this presentation to announce the governance changes - Ignacio Prim Martínez and Guillermo Comenge Valencia joining the board at the December extraordinary meeting. This was transparent forward communication: rather than simply filing the board changes after the fact, management incorporated the upcoming governance transition into the Q3 investor communication.

The FY 2025 presentation (February 6, 2026) confirmed the full-year numbers and formally opened the transition to the new strategic era. Management stated the new 2026-2031 strategic plan would be communicated "shortly." They delivered on this: the plan was confirmed for presentation on May 21, 2026, approximately 3.5 months after the FY 2025 results - a reasonable timeline. The dividend proposal of €0.53/share (+18%) was described as fulfilling the Board's commitment to "sustainable, growing shareholder returns." The FY 2025 dividend exceeded FY 2024's approximately €0.449/share by the guided 18%+, representing delivery on a stated capital return commitment.

The Q1 2026 presentation (May 4, 2026) is the one where management faced the hardest credibility test. Net profit fell 32.6% year-over-year - a sharp decline that demanded explanation. Management's response was precise and verifiable: a national doctors' strike in January-February caused temporary reduction in hospital prescriptions, affecting the Mobility & Healthcare division; adverse weather additionally reduced elective patient mobility; the Medical Technologies segment grew 5% regardless. The key evidence management offered to support the "temporary" characterization was March 2026 data showing +4% year-over-year growth - a single month of normalized data. The speed and specificity of the recovery narrative suggests management had visibility into March results by the time the Q1 presentation was filed on May 4, which validates the confidence behind calling it temporary. The gross margin actually improved 30bps to 50.6% despite the revenue disruption - an outcome inconsistent with a structural business deterioration.

The overall pattern across four periods is one of management that communicates clearly, moves from plan to execution in documented steps, and provides specific data when earnings disappoint. There are no evident cases of guidance being quietly dropped or past commitments being reframed after the fact. The one area where language remains appropriately vague is the new strategic plan - rather than pre-announcing specific targets before May 21, management has signaled intent without numbers. This is appropriate discipline; premature specific targets for a six-year plan would be imprudent.

10. SHAREHOLDER FRIENDLINESS INDEX

Dividends: Prim has paid dividends consistently since the mid-1990s and through the full cycle. The trajectory over the last three fiscal years shows deliberate growth: the FY 2023 dividend (paid out in calendar 2024) was approximately €0.36/share; the FY 2024 dividend was approximately €0.449/share; the proposed FY 2025 dividend is €0.53/share - representing approximately 18% growth year-over-year in 2025 after multi-year compounding. The proposed FY 2025 total dividend payment of €9 million represents a 54% payout ratio against net profit of €16.7 million - a conservative ratio that leaves room for both reinvestment and continued dividend growth. The 10-year dividend growth rate is approximately +15%, though the 5-year rate is slightly negative at -4.89%, reflecting COVID-era disruptions that have now been fully recovered and exceeded. The Board has been explicit about its commitment to growing shareholder returns: the President Lucía Comenge stated that "the Board fulfilled commitments to sustainable, growing shareholder returns" in the FY 2025 communication.

Buybacks and dilution: A share buyback program was approved in January 2021 (inside information filing with CNMV, January 29, 2021). The company maintains a liquidity program (operated through market transactions under CNMV-regulated terms) to support share liquidity rather than as an aggressive buyback vehicle. Shares outstanding have remained approximately stable at 17,036,578 over recent years, with no evidence of meaningful dilution from option programs or new share issuances, and no evidence of substantial share count reduction from buybacks. The net effect is essentially flat shares outstanding - neither a buyback signal nor a dilution concern.

Verdict: Returns Capital - consistent growing dividend with a 10-year track record, a clean balance sheet, and explicit Board commitment to further growth, though the buyback program has not been used aggressively as a capital return tool.

11. INSIDER ACTIVITIES

Primary source: CNMV regulatory filings for PRIM, S.A. (NIF: A28165587), accessed May 18, 2026. Under EU Market Abuse Regulation Article 19, PDMR transactions must be notified to the CNMV within 3 business days.

Recent transactions (last 12 months: May 2025 - May 2026)

After a genuine attempt to access the CNMV's PDMR transaction database for Prim SA - through multiple pathways including the CNMV's "Otra Información Relevante" portal, "Información Privilegiada" section, and "Comunicaciones de Directivos" - no documented open-market purchases or sales by directors or senior managers were accessible in the 12-month window. The CNMV's online database for director dealings was inaccessible through the research pathways used (returning HTTP 403 errors), and search-indexed versions of these specific notifications did not appear in Spanish financial media for this period, suggesting either that no material PDMR transactions occurred or that they were filed in a section of the CNMV portal not indexed by external search engines.

What can be confirmed from CNMV filings and Spanish financial media:

• December 15, 2025: Guillermo Comenge Valencia appointed as dominical (proprietary) board director, representing the Comenge family's interests. This is a governance appointment, not an open-market share purchase. The Comenge family's stake (22.505% held through Mendibea 2002 / La Fuente Salada) has not changed in disclosed filings since October 2023.

• December 15, 2025: Ignacio Prim Martínez appointed as executive director, representing the Prim family's increased operational involvement at board level (5th generation). Similarly a governance appointment, not a market transaction.

• April 7, 2026: CFO Alberto Iriondo announced his departure effective April 30, 2026, after eight years in the role. No share sale associated with this departure was disclosed in CNMV filings or reported in Spanish financial media. His departure was attributed to the conclusion of the 2021-2025 strategic plan and described by the company in positive terms.

Context for absent insider buying data: The Comenge family's most recent significant open-market purchase was in October 2023 (outside the 12-month window), when José Ignacio Comenge elevated his stake from 20.003% to 22.505% through Mendibea 2002, acquiring approximately 3,834,072 additional shares at an approximate market value of €41.6 million. This was a very large open-market purchase by the company's controlling shareholder at a time when Prim's shares were trading below their current levels - a meaningful historical signal of conviction, though now outside the required reporting window.

Net assessment: Within the last 12 months, no confirmed open-market insider share purchases or sales have been identified from primary CNMV sources. The two governance appointments (Comenge Valencia and Ignacio Prim Martínez) represent the controlling families consolidating board-level involvement ahead of the new strategic plan - a constructive signal of family engagement rather than a share transaction signal. The CFO departure does not appear to be associated with any insider sale. Overall, the insider picture for the last 12 months is neutral on a transaction basis, but the structural context of two founding families holding approximately 37% under a syndication pact - and actively increasing board-level representation ahead of a major strategic plan announcement - represents stable alignment between ownership and strategic direction.

12. SCENARIOS

Bull Case

The May 21, 2026 strategic plan announcement defines an ambitious but executable 2026-2031 roadmap: accelerating organic growth in Healthcare Technology through new manufacturer distribution agreements, replicating the Mindray expansion model across additional clinical specialties, and using the clean balance sheet to make one or two targeted inorganic acquisitions in European orthopedics or hospital distribution. The Q1 2026 disruption proves to have been exactly as management described - temporary and non-structural - with Q2 and H2 2026 recovering to 7-8% revenue growth. Gross margin continues to expand beyond 50% as the product mix continues shifting toward higher-value hospital technology and premium orthopedic lines. Project Kairós's CRM implementation starts delivering measurable improvements in sales productivity and customer retention in the orthopedics distribution segment. The new CFO, hired within six months, proves to be a professional who complements the Prim-family executive energy with financial discipline. The Aura Robotics stake begins generating meaningful clinical traction in neurological early diagnosis, opening a new revenue category. By 2028-2029, Prim's narrative transforms from "quality Spanish orthopaedics distributor" to "multi-specialty medical technology and mobility group with European reach." The 10-year dividend growth rate, already 15%, accelerates.

Base Case

The May 21 strategic plan sets a credible 6-8% annual organic revenue growth target with continued margin discipline and selective inorganic activity following the template of the 2022 acquisitions - targeted, sub-€15M deals that add product or geographic capabilities. Q1 2026's disruption normalizes in Q2 and the full-year 2026 growth rate ends somewhere between 5-8%, below 2025's 8% but within the comfortable range. Healthcare Technology continues growing at mid-single-digits through a pipeline of new distribution agreements; Mobility & Healthcare grows at low-single-digits as the Spanish orthopedic market matures. The new CFO is hired within six months and onboards effectively. Gross margin stabilizes around 50-51% with no further significant expansion as the easier pricing gains from the 2021-2025 plan are fully captured. The dividend grows 10-15% per year, consistent with the FY2025 to FY2025 trajectory, supported by steady earnings growth and modest working capital release. Prim remains a well-run niche healthcare company with a loyal investor base attracted to its defensive characteristics, 150-year institutional credibility, and consistent capital return.

Bear Case

The doctors' strike scenario proves to not be an isolated event but a symptom of Spain's healthcare system entering a period of sustained labor tension and public hospital budget constraint. Additional strikes in 2026 and 2027 repeatedly disrupt prescriptions and hospital activity, creating pattern recognition that Prim's earnings are more volatile than its healthcare positioning suggests. Simultaneously, one of Prim's key hospital technology distribution agreements - most likely the Mindray relationship or another significant partnership - is not renewed as the manufacturer decides to build a direct Spanish subsidiary following rapid market share growth. The management transition creates governance friction: the incoming CFO, unfamiliar with Prim's relationship-driven selling model and family governance culture, pursues a different commercial strategy that alienates key hospital department relationships built over years. The new 2026-2031 strategic plan proves overly ambitious on inorganic elements, resulting in an acquisition that underperforms its integration thesis - a repeat of the concern (not yet materialized) that accompanied the 2022 acquisitions of Easytech and Teyder. The combination of earnings volatility, distribution agreement loss, and management transition compresses the confidence premium in Prim's shares. Dividend growth is paused as the Board conserves capital. The 50% gross margin achieved in 2025 cannot be sustained as the mix deteriorates toward lower-margin orthopedic consumables.

Sources:

• CNMV - Other relevant information - PRIM, S.A.
• Prim S.A. Financial Reports 2026 - financialreports.eu
• El Grupo Prim acelera su crecimiento en 2025 con un aumento del 8% en su cifra de negocios - Voz Populi
• Prim eleva un 31.5% su Ebitda hasta septiembre - okdiario
• Prim mantiene ventas en 61.8 millones en Q1 2026 - capital.es
• PRIM publica sus resultados del primer trimestre: ventas de 61.8 millones - Investing.com
• Prim recorta un 32.6% su beneficio - ecobolsa.com
• Prim SA Q3 2025 CNMV presentation
• Prim SA FY2025 annual results CNMV presentation
• José Ignacio Comenge eleva participación en Prim - Valencia Plaza
• PRIM finalises new acquisitions in Italy and Spain - PRIM website
• Prim Alberto Iriondo CFO step down - TradingView
• Spain Medical Devices Market - trade.gov
• PRIM SA Healthcare Technology from Spain
• Prim SA dividend history - digrin.com
• Spain Orthopedic Devices Market Size - marketresearchfuture.com
• Prim earns 51% more in 2023 - PRIM website
• Prim SA company overview - stockanalysis.com
• El Grupo Prim ingresa el 7.7% más en 2024 - El Economista